Olası Trastuzumab kullanımına bağlı gelişen Pyojenik Granülom

Son yıllarda, insan epidermal reseptörü (HER)'nü hedefleyen ilaçlar solid tümörlerin tedavisinde başarılı bir şekilde kullanılmaya başlamıştır. HER 1 inhibitörlerine bağlı çok sayıda kutanöz yan etki bildirilmiş olmasına rağmen, HER 2 ile ilişkili spesifik kutanöz yan etki nadir olarak bildirilmiştir. Trastuzumab HER 2'ye yönelik rekombinant monoklonal bir antikordur ve erken ve metastatik meme kanseri için kullanılmaktadır. Burada meme kanseri için üç haftada bir aldığı trastuzumab tedavisinin onbirinci küründen sonra sol kulak memesinde piyojenik granülom gelişen 47 yaşında bir kadın olgu sunulmaktadır

Possible Trastuzumab induced Pyogenic Granuloma

In recent years, human epidermal receptor (HER) targeted drugs are being used succesfully in the treatment of solid tumors. Alt- hough many cutaneous side effects have been reported due to HER 1 inhibitors, HER 2 associated specific cutaneous adverse effects have been reported rarely. Trastuzumab is a recombinant monoclonal antibody against to the HER 2 and used for early and metastatic breast cancer. We are reporting a 47 year old female who is developed pyogenic granuloma on the left earlobe, after receiving the eleventh cure of triweekly trastuzumab for breast cancer

Kaynakça

Özbayoğlu CA, Aksungur E, Demiröz AS. Alev yanığı zemininde gelişen pyogenik granülom ve literatürün gözden geçirilmesi: Olgu sunumu. Turk Plast Surg 2011;19:27-9.

Paul LJ, Cohen PR. Paclitaxel-associated subungual pyogenic gra- nuloma: report in a patient with breast cancer receiving paclitaxel and review of drug-induced pyogenic granulomas adjacent to and beneath the nail. J Drugs Dermatol 2012;11:262-8.

Rosman IS, Anadkat MJ. Tufted hair folliculitis in a woman treated with trastuzumab. Target Oncol 2010;5:295-6.

Managala R, Aqil F, Gupta RC. Promising molecular targeted the- rapies in breast cancer. Indian J Pharmacol 2011;43:236-45

Baselga J. Treatment of HER2-overexpressing breast cancer. Ann Oncol 2010;21:36-40.

Baker SJ, Reddy EP. Targeted inhibition of kinases in cancer the- rapy. Mt Sinai J Med. 2010;77:573-86.

Morse L, Calarese P. EGFR-targeted therapy and related skin toxi- city. Semin Oncol Nurs 2006;22:152-62.

Alexandrescu DT, Kauffman CL, Dasanu CA. Persistent hair growth during treatment with the EGFR inhibitor erlotinib. Der- matol Online J 2009;15:4.

Segaert S, Chiritescu G, Lemmens L, et al. Skin toxicities of targe- ted therapies. Eur J Cancer 2009;45:295-308.

De Potter IY, Poumay Y, Squillace KA, Pittelkow MR. Human EGF receptor (HER) family and heregulin members are differentially expressed in epidermal keratinocytes and modulate differentiation. Exp Cell Res 2001;271:315-28.

Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006; 6:803-12.

Sibaud V, Dalenc F, Mourey L, Chevreau C. Paronychia and pyoge- nic granuloma induced by new anticancer mTOR inhibitors. Acta Derm Venereol 2011;91:584-5.

Raju DL, Bitzan M. Sirolimus-associated chronic pyogenic periun- gual infection. Kidney Int 2007;71:476.

Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005;6:491-500.

Kaynak Göster